– Additional highlights include pharmacodynamic biomarker analyses from ongoing trial of anti-CD137 antibody, ADG106, in combination with anti-PD-1 toripalimab –
SAN DIEGO and SUZHOU, China, Dec 7 (Bernama-GLOBE NEWSWIRE) — Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced clinical data on its anti-CTLA-4 monoclonal antibody, ADG116, and anti-CD137 agonist, ADG106, in two poster presentations at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) Congress 2021, to be held virtually and in Geneva, Switzerland from December 8 to 11, 2021. Both posters are available in the Publications section of the company’s website at www.adagene.com.
- U.S. Envoy Cuts Short Lebanon Border Tour Amid Protests, Backlash Over Press Remarks
- All UN Security Council Members, Except U.S., Call For Gaza Ceasefire
- Brazil and Israel downgrade diplomatic ties
- UK: Journalists rally in London to support colleagues in Gaza
- China Calls On Israel To Halt Military Operations In Gaza
- Israeli Strikes Hit Southern Damascus Countryside
- Malaysia, Brunei To Boost Economic Ties, Infrastructure Integration
- UN Urges Cessation Of Hostilities To Halt Famine Expansion In Gaza
- Türkiye Delivers Components Of Domestic Steel Dome Air Defence System
- Australia Says Expulsion Of Iranian Ambassador Not Move To Appease Israel